Andere Sprachen Ocumension Therapeutics

Aktien

A2P723

KYG674111011

1477

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:20 26.04.2024			% 5 Tage	% 1. Jan.
6,47 ^HKD	+7,83 %		+8,92 %	-3,14 %

15.04.	Ocumension Therapeutics kündigt klinische Phase III-Studie für OT-502 in China an	CI
08.04.	Augenmedikament von Ocumension Therapeutics schließt klinische Studien ab und wird bald die NDA beantragen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	15.04.
Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	15.04.
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon	08.04.
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China	08.04.
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%	22.03.
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth	21.03.
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints	14.03.
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202	14.03.
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals	17.01.
Ocumension Therapeutics Gets Nod to Register Iluvien in Hong Kong	20.12.
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong	20.12.
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.	13.12.
Ocumension Says Core Product Added to China's National Reimbursement Drug List	13.12.
China Includes Ocumension's Middle Eye Infection Treatment in Drug Reimbursement List	13.12.
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	08.12.
Ocumension Therapeutics Completes Patient Enrollment for Post-Operative Inflammation Drug in China	30.11.
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China	29.11.
Ocumension Therapeutics Plans HK$100 Million Share Buyback	29.11.
Ocumension Enrolls 213 Patients for Phase II Trial of Eye Medication in China	22.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ocumension Therapeutics

Aktien

A2P723

KYG674111011

1477

Andere Sprachen

Filter